Senseonics Holdings Announces $50.0 Million Registered Direct Offering of Common Stock
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and commercialization
of long-term, implantable continuous glucose monitoring (CGM)
systems for people with diabetes, today announced that it has
entered into securities purchase agreements with several
healthcare-focused and other institutional investors to purchase
40,000,000 shares of its common stock in a registered direct
offering at a purchase price of $1.25 per share.
H.C. Wainwright & Co. is acting as the exclusive placement
agent for the offering.
The gross proceeds from the registered direct offering are
expected to be $50.0 million before deducting placement agent fees
and other offering expenses. The Company intends to use the net
proceeds for general corporate purposes. The registered direct
offering is expected to close on or about January 21, 2021, subject
to the satisfaction of customary closing conditions.
The shares of common stock described above are being offered
pursuant to a "shelf" registration statement (File No. 333-235297)
filed with the Securities and Exchange Commission (SEC) and
declared effective on December 20, 2019. Such shares may be offered
only by means of a prospectus, including a prospectus supplement,
forming a part of the effective registration statement. A final
prospectus supplement and the accompanying prospectus relating to
the offering of the securities will be filed with the SEC.
Electronic copies of the final prospectus supplement and the
accompanying prospectus relating to the offering of the shares of
common stock may be obtained, when available, on the SEC's website
at http://www.sec.gov or by contacting H.C. Wainwright & Co.,
LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail:
email@example.com or by telephone: (646) 975-6996.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor there any sales of these
shares in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of such jurisdiction.
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of
transformational glucose monitoring products designed to help
people with diabetes confidently live their lives with ease.
Senseonics' CGM systems, Eversense® and Eversense® XL, include a
small sensor inserted completely under the skin that communicates
with a smart transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
This press release may contain "forward-looking" statements
within the meaning of Section 27A of the Securities Act of 1933,
and Section 21E of the Securities Exchange Act of 1934. These
include statements preceded by, followed by or that otherwise
include the words "believes," "expects," "anticipates,"
"estimates," "projects," "intends," "should," "seeks," "future,"
"continue," or the negative of such terms, or other comparable
terminology. These statements include, without limitation,
statements related to our ability to complete the registered direct
offering, the gross proceeds from the offering and the use of
proceeds. Forward-looking statements relating to expectations about
future results or events are based upon information available to
Senseonics as of today's date and are not guarantees of the future
performance of the company, and actual results may vary materially
from the results and expectations discussed. Additional information
concerning these and other risks is contained in Senseonics’ most
recently filed Annual Report on Form 10-K, Quarterly Report on Form
10-Q, recent Current Reports on Form 8-K and other Securities and
Exchange Commission filings. All subsequent written and oral
forward-looking statements concerning Senseonics, or other matters
and attributable to Senseonics or any person acting on its behalf
are expressly qualified in their entirety by the cautionary
statements above. Senseonics does not undertake any obligation to
publicly update any of these forward-looking statements to reflect
events or circumstances that may arise after the date hereof,
except as required by law.
version on businesswire.com: https://www.businesswire.com/news/home/20210117005052/en/
Senseonics Investor Contact Lynn Lewis or Philip Taylor
Investor Relations 415-937-5406 firstname.lastname@example.org